Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | Twice-yearly infusion for relapsing and primary progressive MS. | Highly effective infusion for MS with a risk of PML. |
| Body system | Brain & Nerves | Brain & Nerves |
| Drug class | Multiple sclerosis therapies | Multiple sclerosis therapies |
| Supply | Prescription only | Prescription only |
| Main uses | Relapsing MS, Primary progressive MS | Relapsing MS, Crohn's disease (US) |
| How it works | Removes immune B cells that drive MS damage. | Stops immune cells from entering the brain. |
| Starts working | Weeks to months | Weeks to months |
| Half-life | About 26 days | About 11 days |
| Typical adult dose | 300 mg IV twice two weeks apart, then 600 mg every 6 months. | 300 mg IV once every 4 weeks (every 6 weeks in some regimens). |
| Forms | IV infusion every 6 months, Subcutaneous injection (some regions) | Monthly IV infusion |
| Common side effects | Infusion reactions, Respiratory infections, Herpes infections | Headache, Tiredness, Urinary infection, Joint pain |
| Serious side effects | Serious infections, Hepatitis B reactivation, Possible increase in breast cancer, PML (rare) | PML (rare brain infection), Liver injury, Allergic reactions |
| Don't take if | Active hepatitis B; Active serious infection | Active serious infection; PML history; Immunosuppression |
| Alcohol | Usually no problem in moderation. No known interaction. | Usually no problem in moderation. No known interaction. |
| Pregnancy | Usually avoidedAvoid unless needed; contraception advised. | Use with cautionLimited data; specialist decision. |
| Breastfeeding | Use with cautionLarge antibody; limited data. | Use with cautionUnknown amounts in milk. |
| In use since | — | — |
| Brand names | United States: OcrevusUnited Kingdom: OcrevusIndia: Ocrevus | United States: TysabriUnited Kingdom: TysabriIndia: Tysabri |
| Legal status | United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM), hospital useIndia: Schedule H | United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM), hospital useIndia: Schedule H |
| ATC code | L04AG08 | L04AG03 |
Taken together
No interaction between these medicines is recorded in the atlas.
Open in the interaction checker